Streetbeat News

Products Services

MU

NVDA

Micron Technology Inc (NASDAQ:MU) shares rose after reporting better-than-expected Q1 revenues. Analysts are optimistic, citing strong pricing rebound in DRAM and NAND, with most raising their price targets. Micron's gross margin and earnings outlook exceeded expectations, and inventory levels are normalizing. The company's HBM3E product is expected to drive demand, particularly with NVIDIA Corp (NASDAQ:NVDA) for its H200 and GH200 offerings. Analysts predict a memory cycle upswing, supported by disciplined supply management and strong AI-driven demand.

Portfolio Pulse from Priya Nigam

December 21, 2023 | 5:18 pm

AISP

BYTS

Airship AI Holdings has completed its business combination with BYTE Acquisition Corp., and the combined company will trade on Nasdaq under the ticker 'AISP' starting December 22, 2023. Airship AI, which provides AI-driven surveillance solutions, has a $163 million pipeline and recently secured $10.9 million in contracts from the Department of Homeland Security. The company targets a rapidly growing edge AI market, projected to reach over $40 billion by 2030, and boasts a blue-chip customer base including federal agencies and Fortune 500 companies. The business combination is expected to enhance Airship AI's visibility, growth, and financial flexibility.

Portfolio Pulse from Benzinga Newsdesk

December 21, 2023 | 5:06 pm

SHW

Argus Research has reaffirmed its Buy rating on Sherwin-Williams (NYSE:SHW), increasing the price target from $330.00 to $378.00. Sherwin-Williams' current share price is $304.21, and the new price target suggests a potential upside of 24.26%. Sherwin-Williams is a leading architectural paint provider in the U.S., with over 4,900 stores.

Portfolio Pulse from Benzinga Insights

December 21, 2023 | 5:00 pm

LQDA

B of A Securities has reaffirmed its Buy rating on Liquidia (NASDAQ:LQDA) and increased its price target from $13.00 to $15.00. Liquidia's shares have risen 3.46% in the last 24 hours to $11.07. The new price target suggests a potential upside of 35.5%. Liquidia is a biopharmaceutical company focusing on pulmonary hypertension treatments, utilizing its proprietary PRINT technology.

Portfolio Pulse from Benzinga Insights

December 21, 2023 | 5:00 pm

CLNN

DMK

HOOK

LGVN

MU

PBLA

PRZO

U.S. stocks traded higher with the Nasdaq Composite gaining over 100 points. Health care shares led gains, while energy shares dipped slightly. Micron Technology (NASDAQ:MU) reported Q1 revenue above estimates but a larger loss per share than expected, and issued strong guidance. ParaZero Technologies (NASDAQ:PRZO), HOOKIPA Pharma (NASDAQ:HOOK), and DMK Pharmaceuticals (NASDAQ:DMK) saw significant stock increases. Panbela Therapeutics (NASDAQ:PBLA), Clene Inc. (NASDAQ:CLNN), and Longeveron Inc. (NASDAQ:LGVN) experienced notable declines. Crude oil prices fell, while gold saw a slight increase.

Portfolio Pulse from Avi Kapoor

December 21, 2023 | 4:59 pm

RDGL

The FDA has granted Breakthrough Device Designation to Vivos Inc.'s RadioGel for treating solid metastatic tumors, particularly in lymph nodes associated with papillary thyroid cancer. RadioGel is an injectable brachytherapy device using yttrium-90 for localized radiation treatment. Vivos Inc. plans to expedite its IDE submission for human clinical trials in collaboration with the Mayo Clinic.

Portfolio Pulse from Javier Hasse

December 21, 2023 | 4:58 pm

DMK

DMK Pharmaceuticals Corporation (NASDAQ:DMK) stock surged after the company announced it has regained full rights to commercialize Zimhi following the termination of its agreement with US WorldMeds, LLC. The company is actively seeking new commercialization opportunities for Zimhi in the U.S., Canada, and Europe. The stock experienced heavy trading volume, with over 27.4 million shares traded, far exceeding its 100-day average volume. DMK's CEO expressed enthusiasm for engaging with new partners to drive growth and maximize shareholder value. The stock price rose by 35% to 80 cents.

Portfolio Pulse from Erica Kollmann

December 21, 2023 | 4:54 pm

DMK

DMK Pharmaceuticals' stock is trading higher following the announcement that the company has regained full rights to commercialize ZIMHI.

Portfolio Pulse from Benzinga Newsdesk

December 21, 2023 | 4:51 pm

SKT

On CNBC, Tanger President and CEO Stephen J. Yalof spoke about current shopping trends and the company's recent acquisitions. He highlighted how these factors are influencing Tanger's business strategy and growth.

Portfolio Pulse from Benzinga Newsdesk

December 21, 2023 | 4:50 pm

GKOS

Glaukos Corp (NYSE:GKOS) shares rose after its iDose TR glaucoma treatment received FDA approval. JPMorgan analyst Allen Gong upgraded Glaukos to Overweight and increased the price target from $66 to $91, citing iDose as a key growth driver. Gong anticipates higher selling prices for iDose, benefits from the adoption of Infinite, and potential gains from iStent due to unfavorable LCDs for competitors. He expects a 'beat-and-raise' story in 2024, with positive estimate revisions for 2025 and beyond.

Portfolio Pulse from Priya Nigam

December 21, 2023 | 4:48 pm